Trials / Completed
CompletedNCT02253654
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 216 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epoetin alfa | Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis. |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-04-27
- Completion
- 2016-05-25
- First posted
- 2014-10-01
- Last updated
- 2017-05-19
- Results posted
- 2017-05-12
Locations
37 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT02253654. Inclusion in this directory is not an endorsement.